Search hospitals

>

Ohio

>

Lancaster

Fairfield Medical Center

Claim this profile

Lancaster, Ohio 43130

Global Leader in Breast Cancer

Global Leader in Lung Cancer

Conducts research for Breast cancer

Conducts research for Ovarian Cancer

Conducts research for Non-Small Cell Lung Cancer

340 reported clinical trials

3 medical researchers

Photo of Fairfield Medical Center in LancasterPhoto of Fairfield Medical Center in LancasterPhoto of Fairfield Medical Center in Lancaster

Summary

Fairfield Medical Center is a medical facility located in Lancaster, Ohio. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Ovarian Cancer, Non-Small Cell Lung Cancer and other specialties. Fairfield Medical Center is involved with conducting 340 clinical trials across 434 conditions. There are 3 research doctors associated with this hospital, such as Timothy D. Moore, John P. Kuebler, and Jarrod T Bruce, MD.

Area of expertise

1

Breast Cancer

Global Leader

Fairfield Medical Center has run 68 trials for Breast Cancer. Some of their research focus areas include:

Stage IV
ER positive
HER2 negative
2

Lung Cancer

Global Leader

Fairfield Medical Center has run 54 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
Stage II
Stage I

Top PIs

Clinical Trials running at Fairfield Medical Center

Lung Cancer

Bladder Cancer

Ovarian Cancer

Breast Cancer

Bladder Carcinoma

Melanoma

Breast cancer

Multiple Myeloma

Esophageal cancer

Cancer

Image of trial facility.

Osimertinib + Bevacizumab

for Lung Cancer

This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.

Recruiting

2 awards

Phase 3

31 criteria

Image of trial facility.

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.

Recruiting

2 awards

Phase 3

27 criteria

Image of trial facility.

Immunotherapy + Targeted Therapy

for Genitourinary Cancers

This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib, nivolumab, and ipilimumab may work better in treating patients with genitourinary tumors that have no treatment options compared to giving cabozantinib, nivolumab, or ipilimumab alone.

Recruiting

1 award

Phase 2

21 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Fairfield Medical Center?

Where is Fairfield Medical Center located?

Who should I call to ask about financial aid or insurance network?

What insurance does Fairfield Medical Center accept?

What awards or recognition has Fairfield Medical Center received?